Liquidia Technologies Operating Income 2018-2020 | LQDA

Liquidia Technologies operating income from 2018 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Liquidia Technologies Annual Operating Income
(Millions of US $)
2019 $-47
2018 $-35
2017 $-28
Liquidia Technologies Quarterly Operating Income
(Millions of US $)
2020-09-30 $-15
2020-06-30 $-14
2020-03-31 $-15
2019-12-31 $-14
2019-09-30 $-13
2019-06-30 $-6
2019-03-31 $-14
2018-12-31 $-10
2018-09-30 $-9
2018-06-30 $-7
2018-03-31 $-9
2017-12-31
2017-09-30 $-8
2017-06-30 $-6
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.144B $0.001B
Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71